| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | -0.24 | 0.2 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.2 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.054 | 0.2 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.25 | 0.2 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.2 |